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Objective To estimate the prevalence and distribution of asymptomatic monosodium 
urate (MSU) crystal deposition in sons of people with gout. 
Method People with gout were mailed an explanatory letter enclosing a postage-
paid study-pack to mail to their son(s) ≥20 years old. Sons interested in participating 
returned a reply-slip and underwent telephone screening. Subsequently they 
attended a study-visit for blood and urine collection, and musculoskeletal 
ultrasonography performed blind to serum urate (SU). Images were assessed for 
A
cc
ep
te
d 
A
rt
ic
le
© 2018 The Authors Arthritis & Rheumatology published by Wiley Periodicals, Inc. on 
behalf of American College of Rheumatology  
double contour sign (DCS), intra-articular or intra-tendinous aggregates/tophi, 
effusion and power Doppler. Logistic regression was used to examine associations.  
Results 131 sons (mean age 43.80 years, body mass index 27.10 kg/m2) completed 
assessments. 64.1% had SU ≥6 mg/dl, and 29.8% had either DCS or intra-articular 
aggregates/tophi in ≥1 joint. All participants with MSU deposition had involvement of 
either 1st metatarsophalangeal joint. 21.4% had intra-tendinous aggregates, and 
these associated with intra-articular MSU crystal deposits (aOR (95%CI) 2.96(1.17-
7.49)). No participant had MSU crystal deposition at SU ≤5 mg/dl, and 24.2% 
participants with SU between 5-6 mg/dl had ultrasonographic MSU deposition. MSU 
crystal deposition associated with increasing SU (aOR (95%CI) 1.61(1.10-2.36) for 
each 1 mg/dl increase). 
Conclusion Asymptomatic sons of people with gout frequently have hyperuricemia 
and MSU crystal deposits. In this study MSU crystal deposits were present in 
participants with SU >5 mg/dl. Evaluation of people without a family history of gout is 
needed to confirm if the threshold for MSU crystal deposition is also lower in the 
general population. 
 
Keywords: Gout, genetics, ultrasonography, uric acid, uric acid excretion  
 
Gout is the commonest inflammatory arthritis and results from persistent 
hyperuricaemia that causes intra- and peri-articular monosodium urate (MSU) crystal 
deposition. It has multiple risk factors including genetic factors that act by modulating 
renal uric acid excretion (1). The heritability of serum urate (SU) and urinary uric acid 
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(UU) excretion is estimated to be c.60% and 60-87% respectively, while the 
heritability of gout is lower at 17.0%, and 35.1% in Taiwanese women and men 
respectively, and was estimated to range between 0% and 58% in a study from the 
USA (1-3). As 14.5-25% people with high SU have asymptomatic MSU crystal 
deposition (4-6), studies that use symptomatic disease phenotype may 
underestimate the heritability of MSU crystal deposition. 
 
The prevalence of asymptomatic MSU crystal deposition in people at high genetic 
risk of gout, e.g. those with a parent with gout is not known. It has implications for 
screening and primary prevention of symptomatic gout, and, contrasts with 
rheumatoid arthritis, whose familial risk and prevalence of autoantibodies in first-
degree relatives is well understood. Thus, the objectives of this study were to [1] 
examine the prevalence and distribution of asymptomatic MSU crystal deposition 
among sons of people with gout; [2] examine the association between SU, age, and 
asymptomatic MSU crystal deposition; and [3] explore whether parental age of gout 
onset associates with asymptomatic MSU crystal deposition in sons. 
Methods: 
Study design: Community based cross-sectional study  
Ethical approval: Nottingham NHS Research Ethics Committee-2 (Rec ref: 
15/EM/0316).  
Recruitment: People with self-reported physician diagnosed gout who participated in 
previous surveys at Academic Rheumatology, University of Nottingham, and 
consented for future research contact were mailed a letter informing them of the 
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study, and enclosing a study pack to post to their sons aged ≥20 years. Sons of 
people with primary gout, attending the Rheumatology Clinic at the Nottingham NHS 
Treatment Centre were approached in a similar manner, and the study was 
advertised on Facebook, and once in a local newspaper. These advertisements were 
targeted at sons living in and around Nottingham who have a parent with gout.   
Sons who returned a reply slip, or contacted us in response to the advertisements 
underwent a screening telephone questionnaire to exclude those with gout (7). The 
screening questionnaire included questions that form part of the eight point chronic 
gout diagnosis (CGD) scale (7). The CGD scale includes current or past history of 
attack of acute arthritis; monoarthritis or oligoarthritis; rapid progression of pain and 
swelling (< 24 hours); podagra; erythema; unilateral tarsitis; tophi; and hyperuricemia 
(7). As SU was not measured at the screening visit in this study, a history of 
hyperuricemia was substituted. Participants scoring ≤3 on the CGD were invited for 
the study visit.  
Study visit:  Participants attended for a study visit at which data on demographic 
characteristics, lifestyle factors, comorbidities, and drug prescriptions were collected. 
Targeted musculoskeletal assessment was performed; height, weight, and blood 
pressure were measured; and random blood and second void early morning urine 
samples were collected. Serum creatinine (SC), SU, and UU and creatinine (UC) 
were measured at the Clinical Pathology laboratories of Nottingham University 
Hospitals NHS Trust. Fractional excretion of uric acid (FEUA) was calculated as (UU 
× SC)/(SU × UC) × 100% (8). 
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Ultrasonography was performed blind to SU level by a rheumatologist with five years 
ultrasonography experience (AA). The ultrasonographic examination involved 
assessment of both 1st metatarsophalangeal joints (MTPJs), talar domes, femoral 
condyles, 2nd metacarpophalangeal joints, wrist triangular fibrocartilages, and 
patellar and triceps tendon insertions (9). These joints and tendons were chosen as 
they have best sensitivity and specificity for differentiating people with gout from 
those with other arthropathies (9). Ultrasound images were scored for double 
contour sign (DCS), intra-articular or intra-tendinous tophi/aggregates, and 
hyperechoic deposits as present or absent as defined by OMERACT (10). Joint 
effusion and power Doppler were graded on 0-3 scale. All ultrasonographic 
assessments were performed using a Toshiba Aplio (8-14 MHz) machine. Doubtful 
images were reviewed by a second ultrasonographer with >15 years of 
ultrasonography experience blind to SU level (PC). For the purpose of this study, 
MSU crystal deposits were defined as present if there was intra-articular DCS or 
tophi/aggregates. Hyperechoic deposits alone were not sufficient to define MSU 
crystal deposits. Where available, data on age of onset of gout and sex of parent 
with gout was extracted from databases held in Academic Rheumatology, University 
of Nottingham, UK.    
Statistical analysis: Mean (standard deviation (SD)), and n (%) were used for 
descriptive purposes. Independent sample t-test, and chi-square test were used for 
univariate analysis. Kruskall-Wallis test was used if the data were non-parametric. 
Logistic regression was used to examine the association between intra-articular 
MSU crystal deposition at any joint in an individual and [1] SU, [2] FEUA, [3] age, 
and [4] intra-tendinous aggregates/tophi at any tendon. The associations were 
adjusted for age in years where required, BMI (Kg/m2), current purine rich alcohol 
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consumption (yes/no), hypertension (yes/no), hyperlipidaemia (yes/no), diabetes 
(yes/no), eGFR (ml/min), and father with gout (yes/no). The individual was the unit of 
analysis for these statistical analyses. Statistical analyses were performed using 
STATA version 15, and p <0.05 was regarded as statistically significant. 
 
Results: 134 participants were recruited into the study, 125 via postal survey 
(number of study packs sent 1,435, replies received 249), six from among sons of 
gout patients attending Nottingham University Hospitals NHS Trust, and three from 
advertisements. The three participants recruited by advertisements did not attend for 
ultrasonographic assessment and are excluded from further analysis. 64.1% and 
29.0% of the participants had SU ≥6, and ≥7 mg/dl respectively. The demographic 
characteristics and comorbidities of the 131 participants included in this study are 
summarised in Table 1. The mean (SD) FEUA was 5.33% (1.87%). 78.6% 
participants with SU ≥ 6 mg/dl had low FEUA defined as FEUA ≤6.6%.  
 
29.8% participants had asymptomatic MSU crystal deposition, and all participants 
with asymptomatic MSU crystal deposition had 1st MTPJ involvement (Figure 1). No 
participant with SU ≤ 5 mg/dl had MSU crystal deposition. Among the 262 1st MTPJs 
examined, intra-articular aggregates were numerically more common than DCS 
(Table 2). Only one participant had DCS at the ankle, and MSU crystal deposits were 
not present at the other joints examined. MSU crystal deposition at the 1st MTPJ 
associated with grade ≥2 effusion at the same joint (aOR (95%CI) 9.44 (3.62-24.63), 
5.44(1.57-18.82) for the right and left sides respectively). Only one 1st MTPJ had 
grade ≥2 power Doppler signal.  
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Hyperechoic aggregates were present in at least one tendon in 28 (21.4%) 
participants. Patellar tendon was involved in 16 (12.2%), and triceps tendon was 
involved in 14 (10.7%) participants respectively (Table 2). Of the 28 participants with 
hyperechoic aggregated in at least 1 tendon, 14 had asymptomatic MSU crystal 
deposition at either 1st MTPJ. MSU crystal deposition at any 1st MTPJ associated 
with hyperechoic aggregates in at least one tendon (OR (95%CI) 3.12 (1.31-7.42). 
This was statistically significant on adjusting for covariates (aOR (95%CI) 2.96 (1.17-
7.49)).  
Participants with asymptomatic MSU crystal deposition had higher SU than those 
without (mean difference (95%CI) 0.54 (0.12-0.96) mg/dl). The prevalence of 
asymptomatic MSU crystal deposition at either 1st MTPJs increased from 0%, to 
24.2%, 39.1%, 29.6%, 44.4%, and 50% respectively in people with SU <5, 5-5.99, 6-
6.99, 7-7.99, 8-8.99, and ≥9 mg/dl respectively (Table 1). The other disease, 
demographic, and laboratory parameters were comparable between the two groups 
(Table 1). MSU crystal deposition associated with increasing SU (OR (95%CI) 1.50 
(1.06-2.11), and aOR (95%CI) 1.61 (1.10-2.36) for each 1 mg/dl increase in SU). 
However, there was no association between MSU crystal deposition and uric acid 
under-excretion status defined as FEUA <6.6% (OR (95%CI) 0.71 (0.29-1.71), and 
aOR (95%CI) 0.78 (0.31-1.98)).  
In those with SUA ≥5 mg/dL (n=117, the cut-off SUA above which MSU crystal 
deposits were present in this study), the prevalence of asymptomatic MSU crystal 
deposition was 33.33%, and increased numerically from the 20s to the 40s before 
stabilising (Table S1). However, this was not statistically significant, and participants 
aged >40 years were not significantly more likely to have asymptomatic MSU crystal 
deposition than those ≤40 years in age (OR (95%CI) 1.32 (0.59-2.95), aOR (95%CI) 
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1.69 (0.34-8.47)). There was no association between hyperuricemia and tendon 
hyperechoic deposits (Table S2), and, in those with SUA ≥5 mg/dl, there was no 
association between increasing age and tendon hyperechoic deposits (Table S3).  
Self-reported data on age of onset of gout was available for 60 parents. The median 
age of onset was 53 years. On univariate analysis, there was no association 
between parental gout onset at or before 53 years of age and asymptomatic MSU 
crystal deposition, with parental gout onset after the age of 53 years as referent (OR 
(95%CI) 2.64 (0.79-8.87). However, this achieved borderline significance on 
adjusting for covariates (aOR (95%CI) 4.14 (0.88-19.46), p=0.07).   
 
Discussion This study demonstrates that the sons of people with gout have a higher 
prevalence of hyperuricaemia (11), uric acid under-excretion (8), and asymptomatic 
MSU crystal deposition than observed in previous studies that preselected 
participants according to their SU level (4-6). It also raises the possibility that MSU 
crystal deposition occurs first in the 1st MTPJs and in tendons before occurring in 
other joints such as the ankle and the knee. However, this observation is limited by 
the cross-sectional study design. It was surprising that one in five people with SU 
between 5-6 mg/dl had ultrasonographic features of MSU crystal deposition at the 1st 
MTPJs. This observation must be interpreted with caution as it is based on a single 
SU measurement, and it is possible that these participants had higher SU previously. 
However, it raises the possibility that the threshold for MSU crystal deposition in vivo 
may be lower than that estimated from laboratory studies. This may be due to the 
fact that the saturation point of urate reduces from 6.75 mg/dl at 37oC to between 4.5 
and 6 mg/dl at 30-35o C, the mean temperature of the human big toe in temperate 
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climates (12, 13). While MSU crystals were present in people with SU between 5-6 
mg/dl, we did not find ultrasonographic evidence of MSU crystal deposition in those 
with SU <5 mg/dl. This raises the possibility that the target SU for treat to target urate 
lowering treatment should be <5 mg/dl at least in people who continue to have gout 
flares despite SU between 5 to 6 mg/dl. However, further prospective studies are 
needed before such a strategy can be recommended. A lower than expected SU 
level in sons of people with asymptomatic MSU crystal deposition might also in part 
be explained by inherited tissue factors (either an increase in promotors or decrease 
in inhibitors) that enhance MSU crystal deposition at relatively low SU levels.  
This study suggests that MSU crystal deposition begins early, in the 3rd decade of 
life, and gets more prevalent with increasing age. The reduction in prevalence of 
MSU crystal deposition in those older than 60 years could be due to the sampling of 
this study, as people older than 60 years with MSU crystal deposits are likely to have 
developed gout flares, and were excluded from this study.  
We observed intra-tendinous hyperechoic deposits in 35.9% people with MSU 
crystal deposits elsewhere. These estimates are consistent with previous reports of 
tendon involvement in gout (14, 15). As shown in Table 2, a substantial proportion of 
tendon hyperechoic deposits occurred in people without ultrasonographic features of 
MSU crystal deposition in the 1st MTPJs. Thus, further research e.g. using dual 
energy CT is required to confirm the composition of these tendinous deposits before 
their presence can be used to imply MSU crystal deposition in the absence of DCS 
or intra-articular tophi in other joints. 
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Our findings suggest that ultrasonographic evaluation of both the 1st MTPJs is 
sufficient to detect all individuals with MSU crystal deposition. Thus, men at a high 
risk of gout, e.g. those with a positive family history could undergo SU measurement 
and ultrasonography of both the 1st MTPJs to screen for MSU crystal deposition. 
While ultrasonographic examination of multiple peripheral joints is time consuming, 
assessment of both the 1st MTPJs takes 10-15 minutes, and may make it possible 
for people with asymptomatic MSU crystal deposits to be diagnosed and to consider 
lifestyle changes to prevent development of symptomatic gout and associated 
consequences. Consideration of pre-emptive pharmacologic urate lowering 
treatment at this early stage would be considered controversial given the absence of 
symptoms and the possibility that many people with asymptomatic MSU crystal 
deposition may not develop gout flares. Such a screening strategy would require 
ultrasonography of three individuals with a SUA ≥ 5 mg/dl to detect one person with 
asymptomatic MSU crystal deposition (number needed to screen = 3). However, in 
the absence of prospective studies evaluating the relationship between 
asymptomatic MSU crystal deposition and symptomatic gout, the benefit from such a 
strategy remains unproven. Our data also suggest that parents with young onset 
gout are more likely to pass on the trait to their sons, although this association was 
not statistically significant and needs a study with a larger sample size. 
However, there are several caveats to this study. Firstly, there was a low response 
rate, and it is possible that people with severe troublesome gout were more likely to 
pass on the study packs to their sons, or for sons with adverse lifestyle risk factors 
were more likely to agree to participate in the study. This raises the possibility of 
selection and response bias. However, the mean (SD) age of gout onset in parents 
of sons who attended for the study visit, and had provided gout specific data at 
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previous research visits (n=60) was 52 (13.65) years, and they reported a mean (SD) 
1.33 (2.10) gout flares in the 12 month period preceding their original research visit. 
These parents also had a low comorbidity burden with median (inter quartile range) 
of 1 (1-2) cardiovascular and renal comorbidities. Secondly, we did not perform joint 
aspiration to confirm the validity of our findings. However, in people with 
hyperuricemia, ultrasonographic changes have 100% sensitivity and 88% specificity 
for MSU crystal deposition compared to joint aspiration (5). Finally, we only 
measured SU on a single occasion. 
In conclusion, this study demonstrates that asymptomatic sons of people with gout 
frequently have hyperuricemia and uric acid under-excretion, and have a high 
prevalence of MSU crystal deposition. This raises consideration of screening of such 
individuals and discussion of early management, involving addressing modifiable risk 
factors (e.g. overweight, obesity, high fructose intake etc.) in order to reduce their 
risk of developing symptomatic gout.  
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Table 1: Disease and demographic characteristics of sons of people with gout  
 
 Total  Asymptomatic MSU crystal deposition
1 
P
2 
Present 
n=39 
Absent 
n=92 
Age, mean (SD) in years 43.80 (11.20) 44.20 (8.91) 43.63 (12.08) 0.79 
 20 to <30 years, n (%) 20 (15.3%) 3 17  
30 to 39 years, n (%) 27 (20.6%) 10 17  
40 to 49 years, n (%) 40 (30.5%) 15 25  
50 to 59 years, n (%) 36 (27.5%) 10 26  
60 to 69 years, n (%) 8 (6.1%) 1 7  
Body mass index, mean (SD) Kg/m
2
 27.10 (4.75) 27.65 (3.99) 26.85 (5.04) 0.38 
Current purine rich alcohol 
consumption, n (%) 
97 (74.1%) 31 (79.5%) 66 (71.7%) 0.36 
Weekly purine rich alcohol intake, 
median (IQR) unit 
10 (5-20) 10 (5-20) 10 (4-20) 0.77 
Hypertension, n (%) 12 (9.2%)
3 
3 (7.7%) 9 (9.8%) 0.715 
Hyperlipidaemia, n (%) 10 (7.6%)
4 
3 (7.7%) 7 (7.6%) 0.99 
Diabetes, n (%) 2 (1.5%)
5 
0 2 (2.2) -/- 
eGFR, mean (SD) ml/min 85.23 (7.19)  85.21 (7.71) 85.24 (7.00) 0.98 
Serum urate, Mean (SD) mg/dL 6.41 (1.13) 
 
6.79 (0.96) 6.25 (1.16) 0.01 
<5 mg/dl, n (%) 14 (10.5%) 0 14  
 
 
 
≥5 and <6 mg/dl, n (%)  33 (26.9%) 8 25 
≥6 and <7 mg/dl, n (%) 46 (34.3%) 18 28 
≥7 and <8 mg/dl, n (%) 27 (20.2%) 8 19 
≥8 and <9 mg/dl, n (%) 9 (6.7%) 4 5 
>9 mg/dl, n (%) 2 (1.5%) 1 1 
Fractional excretion of uric acid (%), 
mean (SD) 
5.3 (1.9) 5.3 (1.7) 5.3 (1.9) 0.91 
Father with gout, n(%) 111 (84.7%) 6 (15.4%) 14 (15.2%) 0.98 
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1All participants with asymptomatic MSU crystal deposition had 1st MTPJ 
involvement. 2Independent sample t-test, Kruskal-Wallis test, and chi-square tests 
were used. 311 prescribed anti-hypertensive drugs (1 on bendroflumethiazide); 46 
prescribed statin; 52 prescribed oral hypoglycaemic drug. Three participants were 
prescribed aspirin. 
 
 
Table 2: Distribution of ultrasound features at different joints and tendons1 
 
 
 N=262 joints 
or tendons 
Asymptomatic MSU deposition in 1
st
 MTPJs  
Present (n=49) Absent (n=213) 
1
st
 meta-tarsophalangeal joints   
Double contour sign 13 (5.0%) -/- -/- 
Tophi 27 (10.3%) -/- -/- 
Double contour sign and tophi 9 (3.4%) -/- -/- 
Grade ≥2 effusion 56 (21.4%) 26 30 
    
Patellar tendon
 
   
Hyperechoic deposits 19 (7.3%) 11 8 
Unilateral 13 7 6 
Bilateral 3 2 1 
Triceps tendon    
Hyperechoic deposits 15 (5.7%) 8 7 
Unilateral 13 6 7 
Bilateral 1 1 0 
 
1 
One participant had double contour sign at one ankle, and, triangular fibrocartilage involvement was 
not observed in any participant. 
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Figure 1: Ultrasonographic evidence of asymptomatic MSU crystal deposition. Left 
panel shows double contour sign in the 1st MTPJ. Middle panel shows intra-articular 
tophus in the dorsal recess with a double contour sign, and the right panel shows 
punctate intra-tendinous hyperechoic deposits.  
 
 
 
 
